In this episode of the DeviceTalks Weekly podcast, Jian Zheng, founder and CEO of Noah Medical, has found entrepreneurial success in robotics, medical devices and a companies that combine both including Intuitive and Auris.

Now, Zheng leads Noah Medical, a robotic bronchoscopy company that’s trying to develop a superior way of diagnosing and treating lung cancer. How does Noah see itself beating Johnson & Johnson MedTech and Intuitive in this competitive space? What areas could Noah focus on next? And where how did the company get the Noah name?

Host Tom Salemi asks these questions and more.

In this week’s FOMO, Sonia Valdes, vice president of life sciences claims at Medmarc, reveals some of the unseen risks and unintended benefits facing the medical device industry coping with new tariffs on medical device imports.

Finally, Chris Newmaker of MassDevice delivers this week’s Newsmakers – Synchron, InBrain, Inspire Medical, Zimmer Biomet, and Olympus.

This episode comes to you courtesy of Medmarc. To learn more, visit: https://medmarc.com/

***

Enjoy the show? Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:05:43) - Synchron raises $200M Series D to support BCI commercialization, next-gen tech
(00:08:30) - InBrain, Microsoft team up on AI for neurology, BCI tech
(00:11:40) - Inspire Medical faces investor class action over Inspire V launch allegations
(00:13:28) - Deloitte accuses Zimmer Biomet of filing ‘through the looking glass’ suit
(00:16:18) - Olympus to cut 2,000 jobs as it unveils new corporate strategy, executive additions
(00:23:45) - FOMO – Sonia Valdes, vice president, life sciences claims, Medmarc
(00:35:15) - Keynote Interview – Jian Zhang, CEO, Noah Medical

Noah Medical’s clear vision for pulmonary bronchoscopy; FOMO: The true costs of MedTech tariffs

DeviceTalks Podcast Network

Noah Medical’s clear vision for pulmonary bronchoscopy; FOMO: The true costs of MedTech tariffs